UOC
IMCR icon

UBS O'Connor’s Immunocore IMCR Stock Holding History

UBS O'Connor’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-53,343
Closed -$1.67M – 359
2025
Q2 		$1.67M Buy
53,343
+8,147
+18% +$253K 0.05% 171
2025
Q1 		$1.34M Sell
45,196
-78
-0.2% -$2.34K 0.03% 160
2024
Q4 		$1.34M Buy
45,274
+10,162
+29% +$321K 0.03% 207
2024
Q3 		$1.09M Sell
35,112
-4,902
-12% -$178K 0.03% 266
2024
Q2 		$1.36M Buy
40,014
+11,090
+38% +$566K 0.04% 253
2024
Q1 		$1.88M Buy
28,924
+1,283
+5% +$88K 0.05% 183
2023
Q4 		$1.89M Sell
27,641
-11,704
-30% -$608K 0.06% 179
2023
Q3 		$2.04M Sell
39,345
-1,000
-2% -$59.2K 0.04% 239
2023
Q2 		$2.42M Sell
40,345
-7,520
-16% -$429K 0.05% 239
2023
Q1 		$2.37M Buy
47,865
+10,613
+28% +$597K 0.06% 285
2022
Q4 		$2.13M Buy
37,252
+2,555
+7% +$144K 0.04% 454
2022
Q3 		$1.63M Sell
34,697
-22,800
-40% -$1.09M 0.02% 675
2022
Q2 		$2.15M Buy
57,497
+19,497
+51% +$633K 0.02% 629
2022
Q1 		$1.14M Buy
+38,000
New +$959K 0.01% 676

Other funds holding IMCR

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

UBS O'Connor's IMCR Position: Q3 2025 in Review

UBS O'Connor sold out of Immunocore (IMCR) in Q3 2025, closing a stake of 53,343 shares — an estimated $1.67M sold.

UBS O'Connor first reported a position in IMCR in Q1 2022 and held it in 14 quarters. The position peaked at $2.42M in Q2 2023. 132 funds tracked by Wall St. Rank hold IMCR as of Q3 2025.

  • UBS O'Connor reported no remaining Immunocore position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 53,343 Immunocore shares in Q3 2025, an estimated $1.67M.
  • UBS O'Connor first reported a position in Immunocore in Q1 2022 and held it in 14 quarters.
  • UBS O'Connor's Immunocore position peaked at $2.42M in Q2 2023.
  • 132 funds tracked by Wall St. Rank held Immunocore as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.